The U.S. Supreme Court decided today to consider the patent-eligibility of isolated DNA sequences by reviewing the Federal Circuit’s decision – Ass’n for Molecular Pathology v. Myriad Genetics, Inc., No. 2010-1406 (Fed. Cir. 2012).
Related Insights
March 5, 2018
Blogs
Advancing Access to Precision Medicine Act – A Bipartisan Bill
On February 15, 2018, representatives Eric Swalwell (CA-15), John Shimkus (IL-15), Scott Peters (CA-52), Erik Paulson (MN-03), and Juan Vargas (CA-51), introduced the Advancing Access to Precision Medicine Act to “provide a study by the National Academy of Medicine on the use of genetic and genomic testing to improve health care.
July 17, 2017
Blogs
Why The Federal Circuit Revisited Written Description
In <EM>Stanford University v. The Chinese University of Hong Kong</EM> (Fed Cir. No 2015-2011, June 27, 2017), the Federal Circuit vacated and remanded interference decisions on the ground the Patent Trial and Appeal Board (“Board”) applied the incorrect standard in determining whether a patent specification satisfies the written description requirement.
March 6, 2017
Blogs
One is Not Enough – Infringement Liability under § 271(f)(1)
The Supreme Court’s decision in Life Technologies Corp. v. Promega Corp. is important for manufacturers of kit components.